Sanofi to acquire Qunol
Paris: Sanofi has announced it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based brand in health & wellness. This transaction will strengthen Sanofi’s Consumer Healthcare’s (CHC) Vitamin, Mineral and Supplements (VMS) category.
"With Qunol’s CoQ10 in heart health and Turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its U.S. portfolio, focused on chronic conditions with growing consumer demand," the release stated. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van Ongevalle, Executive Vice President, Consumer Healthcare, Sanofi said, “The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
Qunol CoQ10 and Turmeric products are both backed by science literature and strong market positioning in their segments. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the U.S.
Peter Boutros, CEO, Quten Research Institute, LLC said, “Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
